A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2010-04-01

Summary

This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.

• Phase: Phase 1

Details

• Lead Sponsor: Pfizer
• Treatments: Carboplatin; Cisplatin; Pemetrexed; Sunitinib